BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17186240)

  • 41. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.
    Yasui H; Hideshima T; Hamasaki M; Roccaro AM; Shiraishi N; Kumar S; Tassone P; Ishitsuka K; Raje N; Tai YT; Podar K; Chauhan D; Leoni LM; Kanekal S; Elliott G; Munshi NC; Anderson KC
    Blood; 2005 Jul; 106(2):706-12. PubMed ID: 15802527
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination therapy with nucleoside analogs and alkylating agents.
    Johnston JB; Verburg L; Shore T; Williams M; Israels LG; Begleiter A
    Leukemia; 1994 Apr; 8 Suppl 1():S140-3. PubMed ID: 8152282
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
    Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
    Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay.
    Zhong Y; Bakke AC; Fan G; Braziel RM; Gatter KM; Leis JF; Maziarz RT; Huang JZ
    Cytometry B Clin Cytom; 2007 May; 72(3):189-95. PubMed ID: 17226861
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
    Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
    Br J Haematol; 2008 May; 141(4):445-53. PubMed ID: 18341636
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.
    Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
    Exp Hematol; 2007 Feb; 35(2):297-304. PubMed ID: 17258078
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Achieving optimal outcomes in chronic lymphocytic leukaemia.
    Hamblin TJ
    Drugs; 2001; 61(5):593-611. PubMed ID: 11368285
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia.
    MacCallum S; Groves M; Brass D; Cunningham J; Sales M; Gelly K; Tauro S
    J Clin Pathol; 2009 May; 62(5):468-70. PubMed ID: 19398596
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
    Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
    Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
    J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.
    Maddocks-Christianson K; Slager SL; Zent CS; Reinalda M; Call TG; Habermann TM; Bowen DA; Hoyer JD; Schwager S; Jelinek DF; Kay NE; Shanafelt TD
    Br J Haematol; 2007 Nov; 139(3):398-404. PubMed ID: 17910629
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bendamustine in chronic lymphocytic leukemia and refractory lymphoma.
    Rummel MJ
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S7-10. PubMed ID: 18760709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.
    McElligott AM; Maginn EN; Greene LM; McGuckin S; Hayat A; Browne PV; Butini S; Campiani G; Catherwood MA; Vandenberghe E; Williams DC; Zisterer DM; Lawler M
    Cancer Res; 2009 Nov; 69(21):8366-75. PubMed ID: 19826055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical studies on NSC290205 aza-steroid alkylator activity in combination with adriamycin against lymphoid leukaemia.
    Trafalis DT; Tsavdaridis D; Camoutsis C; Karayiani V; Mourelatos D; Dalezis P; Athanassiou A; Pangalis GA; Papageorgiou A
    Br J Haematol; 2005 Feb; 128(3):343-50. PubMed ID: 15667536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An "all-oral" combination therapy in chronic lymphocytic leukemia including the oral idarubicin.
    Molica S; Levato D; Di Renzo N; La Sala A; Carotenuto M
    Am J Hematol; 1996 Jul; 52(3):235-6. PubMed ID: 8756100
    [No Abstract]   [Full Text] [Related]  

  • 56. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.
    de Romeuf C; Dutertre CA; Le Garff-Tavernier M; Fournier N; Gaucher C; Glacet A; Jorieux S; Bihoreau N; Behrens CK; Béliard R; Vieillard V; Cazin B; Bourel D; Prost JF; Teillaud JL; Merle-Béral H
    Br J Haematol; 2008 Mar; 140(6):635-43. PubMed ID: 18302712
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
    J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
    Knauf WU; Lissichkov T; Aldaoud A; Liberati A; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Tremmel L; Merkle K; Montillo M
    J Clin Oncol; 2009 Sep; 27(26):4378-84. PubMed ID: 19652068
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination.
    Aleskog A; Norberg M; Nygren P; Rickardson L; Kanduri M; Tobin G; Aberg M; Gustafsson MG; Rosenquist R; Lindhagen E
    Leuk Lymphoma; 2008 Dec; 49(12):2333-43. PubMed ID: 19052982
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Hepatitis B virus reactivation during chlorambucil and prednisolone treatment in an HBsAg-negative and anti-HBs-positive patient with B-cell chronic lymphocytic leukemia].
    Lim SM; Jang JW; Kim BW; Choi H; Choi KY; Park SJ; Han CW
    Korean J Hepatol; 2008 Jun; 14(2):213-8. PubMed ID: 18617769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.